Catamaran Bio, Bio-Techne expand CAR-NK cell collaboration

By The Science Advisory Board staff writers

June 24, 2021 -- Catamaran Bio and Bio-Techne have expanded their collaboration on the development of cell engineering and cell process technologies for Catamaran's manufacturing of chimeric antigen receptor-natural killer (CAR-NK) cell therapies.

Under the collaboration, Bio-Techne will contribute its cell expansion technologies and both companies will contribute expertise to enable large-scale production of functional CAR-NK cells.

Catamaran now has license to Bio-Techne's rights related to the TcBuster transposon system for use in the manufacturing of allogenic cell therapies; it has integrated this system into its CAR-NK Tailwind platform.

The two firms' collaboration began in 2020, they said.

Financial details of the agreement were not disclosed.

Bio-Techne joins Cell and Gene Therapy Catapult PAT consortium
Bio-Techne is joining the Cell and Gene Therapy Catapult process analytical technology (PAT) consortium, which includes over 20 pharmaceutical companies,...
Bio-Techne posts revenue gains in Q3
Bio-Techne reported strong growth in revenues for its third quarter, thanks largely to sales in its protein analysis business.
908 Devices, Bio-Techne partner on protein characterization workflow
908 Devices and Bio-Techne are collaborating to develop an extended workflow solution for protein characterization.
Bio-Techne releases new in situ hybridization assay
Bio-Techne has released DNAscope Assay, a new in situ hybridization assay kit.
Bio-Techne licenses antibody to Xencor
Bio-Techne has licensed an antibody to Xencor for therapeutic development.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter